Viral Vector Contract Development And Manufacturing Organization (CDMO) Market | Key Growth Factors, Business Outlook, and Trends up to 2030

The Business Research Company’s 2026 market reports introduce new features such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, all designed to enhance the depth, usability, and strategic value of the insights provided.

What Is the Expected Market Growth Rate for the Viral Vector Manufacturing Market?
The viral vector contract development and manufacturing organization (cdmo) market size has grown rapidly in recent years. It will grow from $1.47 billion in 2025 to $1.7 billion in 2026 at a compound annual growth rate (CAGR) of 15.6%. The growth in the historic period can be attributed to growing clinical pipeline of gene therapies, early outsourcing of viral vector production, expansion of academic research collaborations, limited in-house manufacturing capabilities of biotech firms, increasing regulatory approvals for viral vectors.

The viral vector contract development and manufacturing organization (cdmo) market size is expected to see rapid growth in the next few years. It will grow to $3.01 billion in 2030 at a compound annual growth rate (CAGR) of 15.3%. The growth in the forecast period can be attributed to rising commercialization of gene and cell therapies, increasing investments in dedicated viral vector facilities, growing demand for scalable manufacturing platforms, expansion of global cdmo partnerships, advances in high-yield vector production technologies. Major trends in the forecast period include expanding capacity for large-scale viral vector production, increasing adoption of single-use manufacturing technologies, growing demand for end-to-end cdmo services, rising focus on regulatory-compliant cGMP facilities, enhanced integration of advanced analytics in vector manufacturing.

Claim your free report sample now:
https://www.thebusinessresearchcompany.com/report/viral-vector-contract-development-and-manufacturing-organization-cdmo-global-market-report

Which Key Growth Contributors Will Drive the Viral Vector Contract Development And Manufacturing Organization (CDMO) Market in the Next Decade?
The growing investment in gene therapy research is expected to propel the growth of the viral vector contract development and manufacturing organization (CDMO) market going forward. Gene therapy research focuses on exploring methods to alter or regulate genes in human cells to correct genetic disorders or combat various diseases. Investment in gene therapy research is rising due to its potential to provide long-term or permanent cures for previously untreatable genetic diseases, driving strong interest from both healthcare innovators and investors. Viral vector CDMOs support gene therapy research by offering expert knowledge and advanced production facilities to manufacture high-quality viral vectors, which are crucial for the safe and effective delivery of therapeutic genes. For instance, in July 2025, according to the Office for Life Sciences, a UK-based government department, the government has committed up to $800 million (£600 million) to develop one of the world’s most advanced, secure, and AI-compatible health data platforms, integrating genomic, diagnostic, and clinical information at a population level to transform NHS and broader healthcare data into a hub for global research trials and AI investment. Therefore, the growing investment in gene therapy research is driving the growth of the viral vector contract development and manufacturing organization (CDMO) market.

How Is the Viral Vector Contract Development And Manufacturing Organization (CDMO) Market Mapped Across Its Segment Categories?
The viral vector contract development and manufacturing organization (cdmo) market covered in this report is segmented –

1) By Service Type: Process Development, Manufacturing, Analytical Testing, Fill-Finish, Other Service Types
2) By Vector Type: Adenoviral Vectors, Lentiviral Vectors, Adeno-Associated Viral Vectors, Retroviral Vectors, Other Vector Types
3) By Workflow: Upstream Manufacturing, Downstream Manufacturing
4) By Application: Gene Therapy, Vaccines, Cell Therapy, Other Applications
5) By End-User: Pharmaceutical And Biotechnology Companies, Academic And Research Institutes, Other End-Users

Subsegments:
1) By Process Development: Upstream Process Development, Downstream Process Development, Analytical Development, Process Characterization
2) By Manufacturing: Clinical Manufacturing, Commercial Manufacturing, cGMP Manufacturing, Cell Bank Production, Fill-Finish Services
3) By Analytical Testing: Release Testing, Stability Testing, Bioassays, Characterization Studies, Regulatory Compliance Testing
4) By Fill-Finish: Aseptic Filling, Lyophilization, Final Packaging, Cold Chain Management, Labeling And Serialization
5) By Other Service Types: Regulatory Support, Supply Chain Management, Technology Transfer, Clinical Trial Support, Cold Chain Logistics

How Are Current Trends Influencing the Viral Vector Contract Development And Manufacturing Organization (CDMO) Market Growth?
Major companies operating in the viral vector contract development and manufacturing organization (CDMO) market are focusing on developing advanced solutions, such as AAV manufacturing solutions, to support scalable and consistent production. AAV manufacturing solutions involve techniques and systems developed to efficiently produce safe and effective adeno-associated virus vectors for gene therapy. For instance, in August 2025, ProBio, a US-based contract development and manufacturing organization (CDMO), launched cGMP Adeno-Associated Virus (AAV) manufacturing services at its 128,000 sq. ft. cutting-edge facility in Hopewell, New Jersey. This expansion is intended to meet the increasing demand for high-quality viral vector production while demonstrating ProBio’s dedication to supporting the development of innovative gene therapies. The Hopewell facility is purpose-built to provide complete AAV manufacturing solutions in compliance with global regulatory and quality standards. ProBio’s capabilities now include fully integrated services such as GMP plasmid DNA production, AAV vector manufacturing, and final drug product formulation with aseptic fill/finish, all in a single U.S. location. This consolidated approach enhances coordination, reduces process handoffs, and speeds up timelines across the drug development lifecycle.

Which Companies Hold the Largest Share in the Viral Vector Contract Development And Manufacturing Organization (CDMO) Market?
Major companies operating in the viral vector contract development and manufacturing organization (cdmo) market are Thermo Fisher Scientific Inc., Merck KGaA, Lonza Group AG, WuXi AppTec, Samsung Biologics Co. Ltd., FUJIFILM Biotechnologies, Oxford Biomedica Plc, Hillgene, Takara Bio Inc., SkyPharma Production SAS, GeneScript ProBio, Obio Technology Corp. Ltd., VectorBuilder, Charles River Laboratories Pvt. Ltd., Creative Biogene, Esco Aster Pte. Ltd., Genesail Biotech Co. Ltd., CEVEC Pharmaceuticals, Cell and Gene Therapy Catapult, CoJourney, Applied Biological Laboratories Inc.

Get the full viral vector contract development and manufacturing organization (cdmo) market report here:
https://www.thebusinessresearchcompany.com/report/viral-vector-contract-development-and-manufacturing-organization-cdmo-global-market-report

Which Regions Are Forecasted to Experience the Fastest Growth in the Viral Vector Contract Development And Manufacturing Organization (CDMO) Market?
North America was the largest region in the viral vector contract development and manufacturing organization (CDMO) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the viral vector contract development and manufacturing organization (cdmo) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Contact Us:

The Business Research Company: Global Market Research Reports & Consulting | The Business Research Company
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email: info@tbrc.info

Follow Us On:

LinkedIn: The Business Research Company | LinkedIn